Ifosfamide/carboplatin/etoposide (ICE) as front‐line, topotecan/ cyclophosphamide as second‐line and oral temozolomide as third‐line treatment for advanced neuroblastoma over one year of age
Authors:
- A JenknerAJA Jenkner
- L De SioLSL De Sio
- R CozzaRCR Cozza
- C De LaurentisCLC De Laurentis
- A InserraAIA Inserra
- 1 April 2004
- journal article
- clinical trial
- Published by Wiley in Acta Paediatrica
- Vol. 93 (s445) , 6-11
Abstract
Children affected by advanced neuroblastoma have a discouraging prognosis, but intensive induction chemotherapy may increase the complete response rate. The combination of ifosfamide, carboplatin and etoposide (ICE) was used for the first time as front‐line regimen in patients with stage 4 neuroblastoma over the age of 1 y. Similarly, second‐line treatment for children with relapsed neuroblastoma, particularly after high‐dose chemotherapy, has been unsatisfactory. The combination of topotecan and cyclophosphamide was studied in resistant or relapsed solid tumors. Furthermore, there is a need for effective palliative treatment in patients failing therapy. Temozolomide, a new dacarbazine analog with optimal oral bioavailability, is being used in an ongoing phase II study as an alternative to oral etoposide. Seventeen patients with stage 4 neuroblastoma have entered the ICE study; 15/16 (94%) major responses after induction were observed and 6/16 (37%) evaluable patients are disease free after a median of 51 mo. Twenty‐one patients with relapsed/refractory disease (of whom 13 neuroblastomas) entered the topotecan/cyclophosphamide study: 7/21 (33%) patients responded. Forty‐one patients entered the temozolomide study (of whom 16 had neuroblastomas): stable disease and symptom relief were obtained in 15/30 (50%) evaluable patients. Intensive induction with ICE resulted in a faster response with high response rate; a larger study with longer follow‐up is needed to confirm a survival advantage. Second‐line treatment was effective in obtaining remissions, some of them long lasting. Third‐line treatment did not elicit measurable responses in neuroblastoma, but achieved prolonged freedom from disease progression and excellent palliation in several patients.Keywords
This publication has 7 references indexed in Scilit:
- Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines*†Medical and Pediatric Oncology, 2001
- Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumorsMedical and Pediatric Oncology, 2000
- Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic AcidNew England Journal of Medicine, 1999
- Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children's Cancer Group.Journal of Clinical Oncology, 1998
- Topotecan in Pediatric Patients With Recurrent and Progressive Solid TumorsJournal of Pediatric Hematology/Oncology, 1998
- Ifosfamide/Carboplatin/Etoposide (ICE) for Recurrent Malignant Solid Tumors of ChildhoodJournal of Pediatric Hematology/Oncology, 1995
- Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: Preliminary resultsEuropean Journal of Cancer, 1995